Loading
A phase 3 trial of Eribulin, Capecitabine, Gemcitabine and Vinorelbine in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer is a phase 3 interventional study registered as NCT06081959 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 376 participants planned, started 2023-10-31 and due to reach its primary completion in 2026-12-31. Interventions recorded: SKB264, Eribulin, Capecitabine, Gemcitabine and Vinorelbine.
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
Shares Sichuan Kelun-Biotech, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Eribulin, Capecitabine and the tag pipeline.
Shares Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
Shares Eribulin, Capecitabine, Gemcitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.